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ABSTRACT 
Traditional pipelines feeding drugs coming to the market are 
declining. This is one of the reasons why nowadays the previous ly 
abandoned natural extract drug discovery programs are slowly 
coming back. In this scenario, small molecular metabolites from 
plants and single cell marine or soil organisms are gaining interest 
in pharmaceutical research again. Animal venoms are another 
source for finding new biopharmaceutical lead molecules and 
research interest in discovering bioactive molecules from venoms 
is rising. Venoms comprise often highly selective and potent 
bioactive peptides and small proteins for receptors and enzymes 
that are valid drug targets. This work discusses drug discovery 
research on bioactive compounds in venoms and gives older and 
more recent examples of bioactive compounds found in venoms 
from different animals. Common pharmaceutical targets that 
different classes of venom toxins interact with and information on 
developmental stages of several medicinal venom peptides are 
also discussed.  
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INTRODUCTION 
Bioactive peptides are widespread in 
prokaryotic and eukaryotic organisms. In 
particular, animal venoms have been the origin 
of several peptide based drugs (Koh and Kini, 
2012). Venom drug discovery programs have 
delivered drugs such as Captopril, Prialt, 
Integrilin and Byetta, and many candidates are 
now progressing in clinical trials. Furthermore, 
peptides derived from venoms are valid 
pharmacological tools to study diseases 
(McCleary and Kini, 2013). For example, a 
study on the snake toxin α-bungarotoxin led to 
the isolation of the nicotinic acetylcholine 
receptor (nAChR) and a new understanding of 
the disease myasthenia gravis (Kini and Doley, 
2010). Captopril is an inhibitor of the 
angiotensin converting enzyme (ACE), used to 
treat high blood pressure (Laing and Moura-da-
Silva, 2005), which is based on compounds 
discovered in the venom of the Brazilian snake 
Bothrops jararaca. Other venom-derived 
bioactives include the highly potent analgesic 
hannalgesin (Pu et al., 1995) from the venom of 
the King cobra, and the antithrombotic drug 
Aggrastat from the venom of the saw-scaled 
viper. Venoms also contain potent 
antimicrobial peptides and there has been an 
increasing stream of publications and patent 
applications relating to antimicrobial 
compounds from venoms. Examples are the 
peptide vgf-1 from venom of the Chinese 
cobra Naja atra, which is active against 
multidrug resistant Mycobacterium tuberculosis (Xie 
et al., 2003), and the peptide microporin from 
the venom of the scorpion Isometrus maculates 
that is highly effective against multiple 
antibiotic resistant bacteria (Zhao et al., 2009). 
Other examples include opistoporins from 
scorpion venom (Moerman et al., 2002), the 
cupiennins, anoplin, parabutoporin (Remijsen et 
al., 2010), vejovine, hadririne, pandinin and so 
on. The number and diversity of bioactive 
peptides in venoms, and the many thousands of 
animal species that produce them (including 
various species of snake, scorpion, spider, bee, 
wasp and cone snail) means that venoms 
constitute huge libraries of potentially new 
drugs and useful research tools. 
 
VENOM TOXINS AND THEIR 
PHARMACEUTICAL POTENTIAL 
Venomous animals use venoms, which 
are complex mixtures consisting for the  major 
part of peptides and enzymes, for prey 
acquisition, digestion and/or defense against a 
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predator. From a historical point of view, 
venoms from snakes for example have been 
used for arthritis and gastrointestinal problems 
as well as conditions such as pain and 
rheumatism to polio. Other examples comprise 
venoms from spiders for treatment of for 
example asthma and cancer. Besides snakes, 
many other organisms produce various forms 
of toxins for defensive and/or offensive 
situations. These organisms include jellyfish, 
scorpions, centipedes, anemones, and some 
venomous fish species (Lewis and Garcia, 
2003). These venom cocktails provide a rich 
source of bioactive peptides with many diverse 
potential therapeutic effects. From these, 
chemotherapeutic, anticoagulant, antidiabetic, 
thrombolytic, immunosuppressive, anticancer, 
antihypertensive, antibacterial, antiarrhythmic, 
and analgesic compounds can be named (Lewis 
and Garcia, 2003; Xu et al., 2006; Khunsap et 
al., 2011; Koh and Kini, 2012). A review from 
2014 thoroughly discusses toxins from venoms 
in drug discovery and development pipelines 
(Harvey, 2014).  
The composition of venom varies across 
species. Venomous animals that immobilize or 
kill prey by venom injection followed by venom 
mediated digestion, contain neurotoxins and/or 
highly active digestive enzymes. The toxins in 
snake venoms among others are toxins that 
target neurotransmitters and ion channels, and 
toxins targeting the muscular, cardiovascular 
and immune system (Koh et al., 2006). Bees, 
wasps and ants use their venom for defense 
when they are threatened, inducing 
inflammatory, immunological, pain inducing, 
headache, and/or swelling as responses after 
injection.  (King and Spangfort, 2000). Besides 
venoms, some organisms (mostly parasites) try 
to avoid attention of their host and as such use 
their venom (more often called saliva) to locally 
prevent immune responses, and use local 
anesthetics to prevent getting their presence 
noticed. Additionally, anticoagulants are 
injected to prevent coagulation of host blood 
(Motoyashiki et al., 2003). A comprehensive 
review from 2014 on toxins, and their analogs, 
derived from venoms in drug discovery is 
thoroughly described by Harvey (Harvey, 
2014). Many toxin derived compounds in the 
have entered clinical trials (King, 2011). But the 
same as in traditional small molecule drug 
development, also many of them fail reaching 
the market with as main causes lack of efficacy, 
toxicity effects, or economic reasons. 
Snake venoms are continuously being 
explored for new peptides and proteins with 
medicinal properties for a wide range of 
syndromes and diseases (Pu et al., 1995; King, 
2011; Diochot et al., 2012; Earl et al., 2012; Koh 
and Kini, 2012; Vink et al., 2012). One source 
of venom toxins relevant to both medicine and 
as pharmacological tools are cone snail venoms 
(Lewis and Garcia, 2003; Twede et al., 2009, 
Essack et al., 2012; Vetter and Lewis, 2012). 
The biggest success was the market approval of 
Prialt (Ziconotide) for treatment of patients 
with severe chronical pain. Ziconotide is a 
peptide drug initially discovered in Conus 
magus which actions by blocking the spinal 
cord resided N-type calcium ion channel 
Cav2.2 (Pope and Deer, 2013). Other 
conopeptides have been discovered that target 
sodium ion channels and several receptors 
(Vetter and Lewis, 2012). When focusing on 
pharmacological tools, a-bungarotoxins and 
conotoxins are important compounds in 
studying subtype selectivity between nicotinic 
acetylcholine receptors, by selectively blocking 
them (Lewis et al., 2012). The pharmacological 
sites of five of the voltage-gated sodium 
channels for example were defined by venom 
toxins (Klint et  al., 2012). Sea anemones are 
other marine species with venom toxins that 
have potential medicinal properties. For 
example the synthetic peptide derived from the 
sea anemone Stichodactyla helianthus. This 
peptides blocks the potassium ion channel 
Kv1.3 very selectively and as such has potential 
medicinal effects in autoimmune diseases 
and/or MS (Beeton et al., 2011; Chi et al., 2012).  
Saliva from parasitic species is per 
definition not a real venom, but it is a biological 
matrix with high potential for finding novel 
bioactive compounds for drug discovery 
pipelines. In saliva from parasites, compounds 
with anti-coagulation properties are found 
which for example aids in treatment of 
cardiovascular diseases (Stibraniova et al., 2013). 
Arthropods have anti-coagulating (such as anti-
platelet proteins), anti-inflammatory, and 
vasodilating proteins in their saliva. This allows 
them to feed from the host for longer periods 
of time without getting noticed by the host, and 
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without blood clotting occurring around the 
area of feeding (which allows detachment from 
the host after feeding). These compounds 
possess very interesting properties from a 
biopharmaceutical point of view. An added 
advantage of lead compounds developed from 
salivary proteins is that they are often anti-
immunogenic and antigenic. This reduces 
probability of immunogenic side effects 
(Schwalie and Schultz, 2009, Stibraniova, 
Lahova et al., 2013). Other effects known to be 
exerted by compounds in saliva from certain 
ticks and mosquitos are vasodilation, migration 
of leukocytes, platelet aggregation, coagulation 
(Mizurini et al., 2013), angiogenesis, and 
complement activation. One specific class of 
salivary proteins are the evasins from tick 
saliva, and aegyptin from moquito saliva (Calvo 
et al., 2007; Deruaz et al., 2008; Deruaz et al., 
2013; Mizurini et al., 2013). Evasins are 
chemokine-binding proteins. Evasin-1 binds to 
CCL3, CCL4 and CCL14, evasin-3 binds to 
CXCL8 and CXCL1, and evasin-4 binds to 
CCL5 and CCL11 (Deruaz et al., 2008), while 
other proteins have also been found with 
chemokine modulating activity (Hajnicka et al., 
2001). Examples of potential medical uses 
involving evasins are evasin-1 for treatment of 
idiopathic pulmonary fibrosis (Russo et al., 
2011) and evasin-4 for treatment of post-
infarction myocardial survival (Braunersreuther, 
Montecucco et al., 2013). Aegyptin, found              
in saliva from a mosquito, is a collagen           
binding protein that inhibits the aggregation 
and adhesion of platelets (Calvo et al., 2007, 
Mizurini et al., 2013).  
 
PHARMACEUTICAL TARGETS OF 
VENOM TOXINS 
Antiplatelet agents 
Targets of anti-platelet compounds in 
some venoms include thrombin, ADP 
receptors, integrins and metalloproteinases. 
Disintegrins from several snake venoms 
function as agonist (thereby preventing the 
binding of fibrinogen) (Bledzka et al., 2013). 
Integrin α2β1 for example is responsible for 
platelet adhesion and agonistic lectin-like 
proteins have been found in venoms from 
snakes (Arlinghaus and Eble, 2012). Some 
three-finger toxins have anti-platelet activity 
(Chanda et al., 2013), while venom derived 
metalloproteinases disrupt platelet adhesion 
and aggregation (Santos-Martinez et al., 2008).  
 
Pro- and anti-coagulant agents 
Many snake venoms have thrombin like 
enzymes which show similarity to thrombin, an 
important enzyme in the coagulation             
cascade (Valeriano-Zapana et al., 2012), while 
prothrombin activators are also found in snake 
venoms with comparable functions as Factor X 
(Tans and Rosing, 2001; Joseph and Kini, 2004, 
Segers et al., 2006). Thrombin inhibitors and 
activators have also been identified in snake 
venoms, and these inhibitors can act as 
potential anti-coagulation agents (Matsui et al., 
2000). After the bleeding of a wound stops the 
clot must dissolve again, which is facilitated by 
fibrinolysis for which the serine proteinase 
plasmin is responsible. In this process, fibrin is 
converted into soluble products. Dissolving 
clots has potential therapeutic applications and 
as such fibrin(ogen)olytic enzymes (e.g. serine 
proteinases and metalloproteinases) from snake 
venoms are interesting to study from a 
pharmaceutical point of view (Lu et al., 2005). 
For hypertension, the angiotensin converting 
enzyme (ACE) is a major target (treatment of 
hypertension and heart failure), and is of 
interest in cardiovascular diseases and diabetic 
nephropathy (Kearney et al., 2005). Next to 
many ACE inhibiting compounds identified in 
plants (Somanadhan et al., 1999), venoms 
comprise another source of candidate peptides 
with ACE inhibiting potential. Captopril in this 
regard is the best known example of an ACE 
inhibiting drug derived from snake venom. 
Many proteins found in tick and mosquito 
saliva targeting coagulation, such as thrombin 
and factor Xa inhibitors (Lai et al., 2004), and 
platelet aggregation inhibitors (Sun et al., 2006), 
are interesting study for their potential as anti-
coagulation agents. Yet other targets of tick 
salivary proteins are T-cells, B-cells, dendritic 
cells and complement factors C3 and C5 in a 
immunosuppressive manner (Hajnicka et al., 
2011; Wikel 2013).  
 
Antibacterials, antifungals and 
antivirals 
Certain wasps procreate by injecting 
their offspring into parasitized species and to 
prevent infection, defensin-like antimicrobial 
Pharmaceutical Properties of Venom Toxins  
Volume 27 Issue 1 (2016)  4 
peptides are present in the venom of these 
wasps (Ye et al., 2010). Other antibacterial 
peptides found in venoms comprise the 
peptides pilosulin 3 and 4 found in a jumper 
ant (Inagaki et al., 2004), although these 
peptides also possess allergenic properties. 
Venom and/or saliva from many honeybees 
have antifungal activity. Also, the larvae of 
some bees have antibacterial and antifungal 
secretions to protect their bee hives (Ergin et 
al., 2006). Melittin for example, a protein found 
in honeybee venom, has antiviral properties 
against different viruses such as HIV-1 and the 
herpes simplex virus (Wachinger et al., 1998). 
As this compound is also hemolytic and an 
allergen, the interest in its medicinal properties 
are limited, but it does stay a valid starting point 
for development of more suitable derivatives. 
 
Anticancer agents 
Bee venom has several desirable 
pharmacological effects such as anti-
inflammatory, antimutagenic, radioprotective, 
and anticancer effects. For the reported 
anticancer effects, induction of apoptosis and 
necrosis, and growth inhibition can be named 
(Jang et al., 2003; Hu, Chen et al. 2006; Han et 
al.; 2007). The venom derived phospholipase 
A2 crotoxin interacts with the epidermal 
growth factor receptor and showed activity in a 
phase I clinical trial, next to showing activity in 
several cell lines. Apamin, which is yet another 
bee venom toxin, can activate p53 in certain 
tumors which can lead to a reduction in tumor 
growth (Orsolic, 2012). Integrins are suggested 
as drug targets for cancer cell adhesion, 
migration and angiogenesis inhibition. In the 
example of contortrostatin, a disintegrin from 
snake venom, it proved effective in inhibiting 
tumor growth, angiogenesis and metastasis in 
ovarian and breast cancer. Additionally, other 
disintegrins targeting integrin α1β1 have 
demonstrated reduction of angiogenesis and 
metastasis (Koh and Kini, 2012). 
 
Ion channel targets 
Major targets of venom toxins are ion 
channels, which are also important 
pharmaceutical targets for among others 
neurodegenerative and pain related diseases. 
Animal toxins targeting ion channels are mainly 
short to medium sized peptides found in a large 
variety of species. Venom toxins are known to 
very specifically and often very potently (in 
different modes; e.g. agonistic or antagonistic 
manner) target different ion channels such as 
voltage-gated potassium, sodium, and calcium 
channels, and also ligand-gated nicotinic 
acetylcholine receptors (Dutertre and Lewis, 
2010). In venom cocktails they mainly act as 
neurotoxins, but individually many are highly 
selective and potent and as such are considered 
as biopharmaceutical candidates and/or 
pharmacological tools (Joseph and Kini, 2004; 
Barber et al., 2013; Brady et al., 2013, Min et al., 
2013; Kularatne and Senanayake, 2014; Tsetlin, 
2015). The neurotoxin alpha-cobratoxin for 
example might be interesting in relation to 
multiple sclerosis (Reid, 2007). Another 
example, Prialt, was developed from a 
conotoxin and is a potent drug against severe 
chronical pain.  
 
CONCLUSION 
Venoms are a promising source for 
finding novel bioactives targeting several 
enzymes and receptors involved in disease. 
Drug discovery approaches focussing on 
venom derived bioactives demand a different 
workflow than traditional small molecule drug 
discovery and development pipelines. Venom 
derived biopharmaceutical lead compounds are 
discovered and developed in a way that 
combines both traditional small molecular drug 
discovery, biopharmaceutical research, and 
traditional natural extract drug discovery 
programs (i.e. from plants). For venoms, the 
discovery and identification aspect is in part 
similar to traditional natural extract drug 
discovery programs. With venom derived drug 
discovery, however, straightforward medicinal 
peptide synthetic approaches can be used to 
optimize leads pharmacologically and 
toxicologically, which is often more 
complicated in case of small molecules 
identified from plant extracts. Furthermore, 
bioactive peptides and proteins can be over-
expressed and produced in large fermentors 
that are also applied standard 
biopharmaceutical development processes. In 
case of venom peptides, genetic modification 
allows structural modification of the peptides 
for pharmacological optimization purposes. By 
rationally modifying amino acids of these 
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bioactive peptides, their pharmacological 
properties can be altered and optimized. 
Venom based drug discovery processes and 
academic research is not mainstream yet, but it 
is expected that it will slowly gain more interest 
and volume considering the many different 
highly potent and selective compounds that are 
yet to be discovered from venoms. As this field 
of research is strongly technology driven, 
advancements in analytics, biotechnology, 
biology, biochemistry, and peptide synthesis all 
are expected to contribute to better and more 
efficient drug discovery from the exiting natural 
recourses that venoms are. 
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